LT-02

DRUG4 trials

Sponsors

Lipid Therapeutics GmbH, Dr. Falk Pharma GmbH, Prometheus Laboratories

Conditions

Abdominal PainDiarrheaLarge IntestineUlcerative Colitis

Phase 2

A Study to Investigate the Efficacy of LT-02 in Patients With Mesalazine Refractory Ulcerative Colitis

Lipid Therapeutics GmbHAbdominal Pain, Diarrhea, Large Intestine +1

Start: 2009-12-31End: 2012-02-29Updated: 2011-11-16

Phase 3

Phosphatidylcholine (LT-02) for Induction of Remission in Ulcerative Colitis

TerminatedNCT02142725

Dr. Falk Pharma GmbHUlcerative Colitis

Start: 2014-07-21End: 2016-12-16Updated: 2017-02-09

Phosphatidylcholine (LT-02) vs. Placebo vs. Mesalamine for Maintenance of Remission in Ulcerative Colitis (PROTECT-2)

CompletedNCT02280629

Dr. Falk Pharma GmbHUlcerative Colitis

Start: 2014-10-01End: 2018-10-05Updated: 2020-01-27

A Study to Investigate the Safety and Efficacy of LT-02 in Patients With Mesalamine Refractory Ulcerative Colitis (UC)

TerminatedNCT02849951

Prometheus LaboratoriesUlcerative Colitis

Start: 2016-07-31End: 2019-08-31Updated: 2017-06-15

Related Papers

Modified-Release Phosphatidylcholine (LT-02) for Ulcerative Colitis: Two Double-Blind, Randomized, Placebo-Controlled Trials.

2023-10-062 citations

First multicenter study of modified release phosphatidylcholine "LT-02" in ulcerative colitis: a randomized, placebo-controlled trial in mesalazine-refractory courses.

2014-05-0683 citations